Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X:
“R/R Ewing Sarcoma
– 108 phase I/II trials (2014–24): 70% academic, 81% multicenter
– Focus: TKIs, PARP, EWSR1::FLI1, cell-cycle inhibitors
– Immunotherapy (mAbs, CAR-T) emerging
– ORR ~8%, DCR ~44%
– Global efforts, need for randomized phase II.”
Title: Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium
Authors: Antonio Juan Ribelles, Arthur Felix, Nuria Benavent, Josep Escrivá-Fernández, Mehdi Brahmi, Nathalie Gaspar, Susanne A. Gatz, Thomas Grünewald, Christina Linder-Stragliotto, Emanuela Palmerini, Pan Pantziarka, Sandra Strauss, Didier Surdez, Pablo Berlanga, Martin G. McCabe
Read The Full Article at JCO Precision Oncology.
More posts featuring Nieves Martinez Lago.